Financial Reporting Document
Annex No. 1 to Resolution No. 079/2022 of the Management Board of
Capital Adequacy and Other Information Subject to Disclosure
of the Alior Bank Spółka
as at
Disclosure Pillar III
List of Tables for the period 2021/12
No. Table
- EU OV1 - Overview of total risk exposure amounts
- EU KM1 - Key metrics template
- EU INS1 - Insurance participations
- EU INS2 - Financial conglomerates information on own funds and capital adequacy ratio
- EU OVC - ICAAP information
EU OVA - Institution risk management approach- EU OVB - Disclosure on governance arrangements
- EU LI1 - Differences between the accounting scope and the scope of prudential consolidation and mapping of financial statement categories with regulatory risk categories
- EU LI2 - Main sources of differences between regulatory exposure amounts and carrying values in financial statements
- EU LI3 - Outline of the differences in the scopes of consolidation (entity by entity)
EU LIA - Explanations of differences between accounting and regulatory exposure amounts- EU LIB - Other qualitative information on the scope of application
- EU PV1 - Prudent valuation adjustments (PVA)
- EU CCA - Main features of regulatory own funds instruments and eligible liabilities instruments
- EU CC1 - Composition of regulatory own funds
- EU CC2 - reconciliation of regulatory own funds to balance sheet in the audited financial statements
- IFRS 9/Article 468-FL - Comparison of institutions' own funds and capital and leverage ratios with and without the application of transitional arrangements for IFRS 9 or analogous ECLs, and with and without the application of the temporary treatment in accordance with Article 468 of the CRR
- EU CCyB1 - Geographical distribution of credit exposures relevant for the calculation of the countercyclical buffer
- EU CCyB2 - Amount of institution-specific countercyclical capital buffer
- EU LR1 - LRSum: Summary reconciliation of accounting assets and leverage ratio exposures
- EU LR2 - LRCom: Leverage ratio common disclosure
- EU LR3 - LRSpl: Split-up of on balance sheet exposures (excluding derivatives, SFTs and exempted exposures)
- EU LRA - Disclosure of LR qualitative information
- EU LIQA - Liquidity risk management
- EU LIQ1 - Quantitative information of LCR
- EU LIQB - Qualitative information on LCR, which complements template EU LIQ1.
- EU LIQ2 - Net Stable Funding Ratio
- EU CRA - General qualitative information about credit risk
- EU CRB - Additional disclosure related to the credit quality of assets
- EU CR1 - Performing and non-performing exposures and related provisions
- EU CR1-A - Maturity of exposures
- EU CR2 - Changes in the stock of non-performing loans and advances
- EU CR2a - Changes in the stock of non-performing loans and advances and related net accumulated recoveries
- EU CQ1 - Credit quality of forborne exposures
- EU CQ2 - Quality of forbearance
- EU CQ3 - Credit quality of performing and non-performing exposures by past due days
- EU CQ4 - Quality of non-performing exposures by geography
- EU CQ5 - Credit quality of loans and advances by industry
- EU CQ6 - Collateral valuation - loans and advances
- EU CQ7 - Collateral obtained by taking possession and execution processes
- EU CQ8 - Collateral obtained by taking possession and execution processes - vintage breakdown
- EU CRC - Qualitative disclosure requirements related to CRM techniques
- EU CR3 - CRM techniques overview: Disclosure of the use of credit risk mitigation techniques
- EU CRD - Qualitative disclosure requirements related to standardised model
- EU CR4 - standardised approach - Credit risk exposure and CRM effects
- EU CR5 - standardised approach
- EU CCRA - Qualitative disclosure related to CCR
- EU CCR1 - Analysis of CCR exposure by approach
- EU CCR2 - Transactions subject to own funds requirements for CVA risk
- EU CCR3 - Standardised approach - CCR exposures by regulatory exposure class and risk weights
- EU CCR5 - Composition of collateral for CCR exposures
- EU CCR6 - Credit derivatives exposures
- EU CCR8 - Exposures to CCPs
- EU-SECA- Qualitative disclosure requirements related to securitisation exposures
- EU MRA - Qualitative disclosure requirements related to market risk
Annex No. 1 to Resolution No. 079/2022 of the Management Board of
No. Table
- EU MR1 - Market risk under the standardised approach
- EU IRRBBA - Qualitative information on interest rate risks of non-trading book activities
- EU IRRBB1 - Interest rate risks of non-trading book activities
EU ORA - Qualitative information on operational risk- EU OR1 - Operational risk own funds requirements and risk-weighted exposure amounts
EU REMA - Remuneration policy- EU REM1 - Remuneration awarded for the financial year
- EU REM2 - Special payments to staff whose professional activities have a material impact on institutions' risk profile (identified staff)
- EU REM3 - Deferred remuneration
- EU REM4 - Remuneration of
1 million EUR or more per year - EU REM5 - Information on remuneration of staff whose professional activities have a material impact on institutions' risk profile (identified staff)
- EU AE1 - Encumbered and unencumbered assets
- EU AE2 - Collateral received and own debt securities issued
- EU AE3 - Sources of encumbrance
- EU AE4 - Accompanying narrative information
- EU KM2 - Key metrics - MREL and, where applicable, G-SII requirement for own funds and eligible liabilities
- Covid19_1 - Information on loans and advances subject to legislative and non-legislative moratoria
- Covid19_2 - Breakdown of loans and advances subject to legislative and non-legislative moratoria by residual maturity of moratoria
- Covid19_3 - Information on newly originated loans and advances provided under newly applicable public guarantee schemes introduced in response to COVID-19 crisis
- Management Board's statement on the liquidity risk
Annex No. 1 to Resolution No. 079/2022 of the Management Board of
Introduction
Information is published in accordance with Commission Implementing Regulation (EU) 2021/637 of
As at
Unless otherwise stated, the information in this document has been disclosed based on the data from the Consolidated Financial Statements of the
Figures are drawn up in Polish zlotys (PLN) and are rounded up to
This version of our report is a translation from the original, which was prepared in Polish language. All possible care has been taken to ensure that the translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions, the original language version of our report takes precedence over this translation.
3
Annex No. 1 to Resolution No. 079/2022 of the Management Board of
EU OV1 - Overview of total risk exposure amounts
PLN m
Total risk exposure amounts (TREA) |
Total own funds requirements |
|||
a |
b |
c |
||
|
|
|
||
1 Credit risk (excluding CCR) |
44 749,1 |
42 792,9 |
3 579,9 |
|
2 |
Of which the standardised approach |
44 749,1 |
42 792,9 |
3 579,9 |
3 |
Of which the Foundation IRB (F-IRB) approach |
- |
- |
- |
4 |
Of which slotting approach |
- |
- |
- |
EU 4a |
Of which equities under the simple riskweighted approach |
- |
- |
- |
5 |
Of which the Advanced IRB (A-IRB) approach |
- |
- |
- |
6 |
Counterparty credit risk - CCR |
530,0 |
1 398,4 |
42,4 |
7 |
Of which the standardised approach |
484,0 |
1 309,7 |
38,7 |
8 |
Of which internal model method (IMM) |
- |
- |
- |
EU 8a |
Of which exposures to a CCP |
- |
- |
- |
EU 8b |
Of which credit valuation adjustment - CVA |
46,0 |
88,7 |
3,7 |
9 |
Of which other CCR |
- |
- |
- |
10 |
Not applicable |
- |
- |
- |
11 |
Not applicable |
- |
- |
- |
12 |
Not applicable |
- |
- |
- |
13 |
Not applicable |
- |
- |
- |
14 |
Not applicable |
- |
- |
- |
15 |
Settlement risk |
- |
- |
- |
16 |
Securitisation exposures in the non-trading book (after the cap) |
- |
- |
- |
17 |
Of which SEC-IRBA approach |
- |
- |
- |
18 |
Of which SEC-ERBA (including IAA) |
- |
- |
- |
19 |
Of which |
- |
- |
- |
EU 19a |
Of which 1250% / deduction |
- |
- |
- |
20 |
Position, foreign exchange and commodities risks (Market risk) |
261,3 |
416,0 |
20,9 |
21 |
Of which the standardised approach |
261,3 |
416,0 |
20,9 |
22 |
Of which IMA |
- |
- |
- |
EU 22a |
Large exposures |
- |
- |
- |
23 |
Operational risk |
3 870,9 |
3 708,3 |
309,7 |
EU 23a |
Of which basic indicator approach |
- |
- |
- |
EU 23b |
Of which standardised approach |
164,7 |
98,9 |
13,2 |
EU 23c |
Of which advanced measurement approach |
3 706,2 |
3 609,4 |
296,5 |
24 |
Amounts below the thresholds for deduc on (subjectto 250% risk weight) |
1 559,8 |
1 524,1 |
124,8 |
25 |
Not applicable |
- |
- |
- |
26 |
Not applicable |
- |
- |
- |
27 |
Not applicable |
- |
- |
- |
28 |
Not applicable |
- |
- |
- |
29 |
Total |
49 411,3 |
48 315,6 |
3 952,9 |
4
Annex No. 1 to Resolution No. 079/2022 of the Management Board of
EU KM1 - Key metrics template
PLN m
a |
c |
e |
||
|
|
|
||
Available own funds (amounts) |
||||
1 |
Common Equity Tier 1 (CET1) capital |
6 200,0 |
6 269,9 |
6 545,2 |
2 |
Tier 1 capital |
6 200,0 |
6 269,9 |
6 545,2 |
3 |
Total capital |
6 997,7 |
7 218,3 |
7 658,4 |
Risk-weighted exposure amounts |
||||
4 |
Total risk exposure amount |
49 411,2 |
48 270,0 |
48 315,6 |
Capital ratios (as a percentage of risk-weighted exposure amount) |
||||
5 |
Common Equity Tier 1 ratio (%) |
12,55% |
12,99% |
13,55% |
6 |
Tier 1 ratio (%) |
12,55% |
12,99% |
13,55% |
7 |
Total capital ratio (%) |
14,16% |
14,95% |
15,85% |
Additional own funds requirements to address risks other than the risk of excessive leverage (as a percentage of risk-weighted exposure amount) |
||||
EU 7a |
Additional own funds requirements to address risks other than the risk of excessive leverage (%) |
- |
- |
- |
EU 7b |
of which: to be made up of CET1 capital (percentage points) |
- |
- |
- |
EU 7c |
of which: to be made up of Tier 1 capital (percentage points) |
- |
- |
- |
EU 7d |
Total SREP own funds requirements (%) |
8,00% |
8,00% |
8,00% |
Combined buffer and overall capital requirement (as a percentage of risk-weighted exposure amount) |
||||
8 |
Capital conservation buffer (%) |
2,50% |
2,50% |
2,50% |
EU 8a |
Conservation buffer due to macro-prudential or systemic risk identified at the level of a Member State (%) |
- |
- |
- |
9 |
Institution specific countercyclical capital buffer (%) |
0,00% |
0,00% |
0,00% |
EU 9a |
Systemic risk buffer (%) |
0,00% |
0,00% |
0,00% |
10 |
|
- |
- |
- |
EU 10a |
Other |
- |
- |
- |
11 |
Combined buffer requirement (%) |
2,50% |
2,50% |
2,50% |
EU 11a |
Overall capital requirements (%) |
10,50% |
10,50% |
10,50% |
12 |
CET1 available after meeting the total SREP own funds requirements (%) |
2,04% |
2,49% |
3,04% |
Leverage ratio |
||||
13 |
Total exposure measure |
85 857,0 |
82 295,2 |
82 258,1 |
14 |
Leverage ratio (%) |
7,22% |
7,62% |
7,96% |
Additional own funds requirements to address the risk of excessive leverage (as a percentage of total exposure measure) |
||||
EU 14a |
Additional own funds requirements to address the risk of excessive leverage (%) |
- |
- |
- |
EU 14b |
of which: to be made up of CET1 capital (percentage points) |
- |
- |
- |
EU 14c |
Total SREP leverage ratio requirements (%) |
3,00% |
3,00% |
0,00% |
Leverage ratio buffer and overall leverage ratio requirement (as a percentage of total exposure measure) |
||||
EU 14d |
Leverage ratio buffer requirement (%) |
- |
- |
- |
EU 14e |
Overall leverage ratio requirement (%) |
3,00% |
3,00% |
0,00% |
Liquidity Coverage Ratio |
||||
15 |
Total high-quality liquid assets (HQLA) (Weighted value -average) |
16 030,8 |
16 276,9 |
16 104,1 |
EU 16a |
Cash outflows - Total weighted value |
12 331,6 |
11 690,6 |
11 129,4 |
EU 16b |
Cash inflows - Total weighted value |
2 310,8 |
1 923,8 |
1 855,2 |
16 |
Total net cash outflows (adjusted value) |
10 020,8 |
9 766,8 |
9 274,2 |
17 |
Liquidity coverage ratio (%) |
159,98% |
166,65% |
173,64% |
Net Stable Funding Ratio |
||||
18 |
Total available stable funding |
66 105,8 |
63 340,9 |
63 485,5 |
19 |
Total required stable funding |
50 211,1 |
48 698,8 |
52 059,6 |
20 |
NSFR ratio (%) |
131,66% |
130,07% |
121,95% |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Disclaimer
PursueCare’s Virtual Addiction Treatment Program Adds In-Person Clinics, Continuing Rapid Expansion
John Hancock — And Much Of Corporate America — Thrived During The Pandemic. Here’s Why.
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News